research use only

Urea

Name: Urea
Brand: Selleck Chemicals
SKU: S3687
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S3687

Urea (Carbonyldiamide, Ureophil) is a highly soluble organic compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.

Chemical Structure

Molecular Weight: 60.06

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S368701 DMSO]12 mg/mL]false]Water]12 mg/mL]false]Ethanol]12 mg/mL]false Purity: 98.63%

98.63

Related Targets	P450 (e.g. CYP17) Dehydrogenase PDE phosphatase PPAR HSP (HSP90) Vitamin Transferase Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase Serine/threonin kinase Lipoxygenase Phospholipase (e.g. PLA) Retinoid Receptor DPP ACE Peroxidases Fatty Acid Synthase FXR HMG-CoA Reductase Carbonic Anhydrase Lipase Decarboxylase DHFR IDO/TDO Hydroxylase PCSK9 OXPHOS ROR
Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Pitstop 2 Sesamin Bilobalide Formononetin Hesperidin Azeliragon (TTP488) L-Mimosine Carbenoxolone Sodium Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate

Chemical Information, Storage & Stability

Molecular Weight	60.06	Formula	CH₄N₂O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	57-13-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Solubility

In vitro
Batch:

DMSO : 12 mg/mL ( (199.8 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 12 mg/mL

Ethanol : 12 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04589065	Suspended	Heart Failure\|Chronic Systolic Heart Failure\|Renal Failure\|Cardiorenal Syndrome	Lenar Yessayan\|University of Michigan	September 2024	Not Applicable
NCT06405555	Not yet recruiting	Heart Failure With Reduced Ejection Fraction\|Hypotension\|LV Dysfunction	Ottawa Heart Institute Research Corporation	August 1 2024	Phase 2\|Phase 3
NCT06390592	Not yet recruiting	Renal Failure\|Chronic Kidney Disease	Fresenius Medical Care Deutschland GmbH\|Alcedis GmbH	June 2024	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):